1[1]Kollmannsberger C, Mross K, Jakob A, et al. Topotecan-A novel topoisomerase I inhibitor: pharmacology and clinical experience [J]. Oncology, 1999, 56(1):1-12. 被引量：1
2[2]von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclopho-sphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer [J]. J Clin Oncol, 1999, 17(2):658-667. 被引量：1
3[3]Frasci G, Panza N, Comella P, et al. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study [J]. Ann Oncol, 1999, 10(3):355-358. 被引量：1
4[4]Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment [J]. Cancer,1981, 47(1):207-214. 被引量：1
5[5]Ormrod D, Spencer CM. Topotecan:a review of its efficacy in small cell lung cancer [J]. Drugs,1999, 58(3): 533-551. 被引量：1
3Gizawy EL, Hedaya MA.Comparative brain tissue distribution of campothecin and topotecan in the rat [ J ] .Cancer Chemother Pharmacol,1999. 43 (5) : 364 - 370. 被引量：1
4Ardizzoni A,et al.Topotecan,a new active drug in secondline treatment of small-cell lung cancer:a phase 11 study in patients with refractory and sensitive disease[J].J Clin Oncol,1997,15(5):2090-2096. 被引量：1
